Protocol Ledger

NCT03643965 · Phase III · COMPLETED

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Interventional Phase III clinical trial protocol NCT03643965 sponsored by Calliditas Therapeutics in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-05 Enrollment: 365 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03643965
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)365 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03643965
Protocol FieldVerified Registry Value
NCT IdentifierNCT03643965
Consolidated Lead SponsorCalliditas Therapeutics
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment365 participants (ACTUAL)
Registered Start Date2018-09-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI